OBJECTIVE To explore the effect of idbenone on non-motor status, miR-486-5p and miR-221 in patients with Parkinson's disease.

METHODS  Ninety-four patients with Parkinson's disease admitted to Zhengzhou Central Hospital from January 2020 to May 2021 were selected and divided into observation group and control group according to random number table method. The control group(n=47) received oral treatment of metoba, and the observation group(n=47) received oral treatment of idbenone on the basis of the control group. After 12 weeks of treatment, clinical efficacy, non-motor status, gait status, brain neurotransmitters(norepinephrine, dopamine and serotonin), miR-486-5p and miR-221 expression were compared between the two groups.

RESULTS  The total effective rate of the observation group was higher than that of the control group(70.21% vs 42.55%) (x²=7.311, P=0.007). Compared with the control group after treatment, the severity and frequency scores of non-exercise state in the observation group were lower(P<0.05). The length of step increase after treatment in observation group was longer than that in control group(P<0.05), and the step speed and step frequency of observation group were lower than that of control group(P<0.05). The levels of norepinephrine, dopamine and 5-hydroxyserotonin in observation group were higher than those in control group(P<0.05). After treatment, the level of miR-486-5p in observation group was higher than that in control group, and the level of miR-221 was lower than that in control group(P<0.05).

CONCLUSION  For patients with Parkinson's disease, idbenquinone can up-regulate the expression level of miR-486-5p, suppress the expression of miR-221, improve the level of brain neurotransmitters, and thus improve the non-motor symptoms and gait of patients.